Background. Current guidelines recommend that all sexually active human immunodeficiency virus (HIV)-infected persons be tested at least annually for syphilis, chlamydia, and gonorrhea. We examined temporal trends in syphilis, chlamydia, and gonorrhea testing among sexually active HIV-infected adults receiving medical care in the United States during 2009-2013.
At the end of 2013, it was estimated that 933 941 persons were living with diagnosed human immunodeficiency virus (HIV) infection in the United States [1] . The Centers for Disease Control and Prevention (CDC) estimates that nearly 20 million cases of sexually transmitted diseases (STDs) occur every year in the United States, and, for the first time since 2006, cases of syphilis, chlamydia, and gonorrhea increased in 2014 [2] . However, national data on HIV and STD coinfection are limited. In 2014, 26 states reported information about the person's HIV status in STD cases and the sex of their sex partners in at least 70% of primary and secondary syphilis cases [2] . HIV and STD coinfection was high, particularly for men who have sex with men (MSM). Among primary and secondary syphilis cases with known HIV status, more than half of reported cases from MSM were HIV positive [2] . In addition, among MSM visiting STD Surveillance Network sites, the prevalence of syphilis, gonorrhea, and chlamydia was higher among MSM living with HIV than among HIV-negative MSM [2] . HIV-infected persons who acquire STDs may be at increased risk of developing complications [3] , and some STDs increase the likelihood of HIV transmission [4] [5] [6] . Therefore, STD diagnosis, treatment, and prevention services are an important part of HIV medical care and can have significant public health benefits [3, 7, 8] .
Current guidelines, which have remained largely unchanged since 2004, recommend that HIV-infected persons be screened at the time of HIV care initiation and that sexually active persons be screened at least annually for syphilis, chlamydia, and gonorrhea [9] [10] [11] [12] [13] [14] ; however, studies suggest that testing is below recommended levels. A recent study that examined STD testing among HIV-infected persons in a large health claims database found that 51% of privately insured persons were tested for syphilis, 22% for chlamydia, and 22% for gonorrhea [15] . A population-based analysis of HIV-infected adults receiving medical care in 2009 found that 55% were tested at least once in the past 12 months for syphilis, and 23% and 24% received at least 1 gonorrhea and chlamydia test, respectively [16] . However, population-based information on trends in STD testing among HIV-infected persons is lacking and of particular importance given the recent increase in STDs. Our objective in this analysis was to examine temporal trends in STD testing among sexually active HIV-infected adults receiving medical care in the United States.
METHODS
We analyzed the most recent available data from the Medical Monitoring Project (MMP; 2009-2013 cycles), an HIV surveillance system designed to produce nationally representative, cross-sectional estimates of behavioral and clinical characteristics of HIV-infected adults receiving medical care in the United States. MMP methods, including sampling, weighting procedures, and response rates, have been described in detail elsewhere [17, 18] . Briefly, during 2009-2013, MMP used a 3-stage, complex sampling design in which US states and territories were sampled, followed by facilities providing outpatient HIV medical care in those jurisdictions, then HIV-infected adults (aged ≥18 years) receiving care in those facilities. All sampled states and territories participated in MMP. From 2009 to 2013, facility response rates ranged from 76% to 85%, and patient response rates ranged from 49% to 55%. Eligible persons were HIV infected, aged ≥18 years, and had received medical care in participating facilities between January and April in the cycle year for which they were sampled. Data were collected from June 2009 through May 2014 using face-to-face or telephone interviews and medical record abstractions. Data were weighted on the basis of known probabilities of selection at state or territory, facility, and patient levels [18] . In addition, predictors of nonresponse were determined from analysis of data from sampled facilities and patients, and data were then weighted to adjust for nonresponse following established methods [19, 20] .
In accordance with the federal human subjects protection regulations [21] and guidelines for defining public health research [22] , MMP was determined to be a nonresearch, public health surveillance activity used for disease control program or policy purposes. Participating states or territories and facilities obtained local institutional review board approval to be part of MMP if required locally. Informed consent was obtained from all interviewed participants.
Definitions
We used medical record data to estimate the prevalence of syphilis, chlamydia, and gonorrhea testing in the 12 months prior to interview. Syphilis testing was defined as a result from nontreponemal or treponemal syphilis test, antibody test, or dark-field microscopy. Chlamydia testing was defined as at least 1 test result from culture, direct fluorescent antibody, enzyme immunoassay or enzyme-linked immunoassay, nucleic acid amplification test (NAAT), or nucleic acid probe. Testing for gonorrhea was defined as documentation of at least 1 test result from culture, Gram stain, NAAT, or the nucleic acid probe. The analysis was limited to persons who reported sexual activity in the past 12 months. We performed stratified analyses according to the sex of participants and their sex partners in the past 12 months (hereafter referred to as sexual behavior). Men who had sex with men only or with men and women were defined as MSM; men who had sex with women only were defined as MSW; women who had sex with men were defined as WSM. Race/ethnicity was defined by self-identification as black or African American non-Hispanic, Hispanic, or white non-Hispanic. Due to small sample sizes, people who reported other or multiple races/ethnicities were combined into a single group (hereafter referred to as other race/ethnicity).
We estimated weighted percentages of persons tested for syphilis and for both chlamydia and gonorrhea in the last 12 months. We estimated each of these 2 outcomes separately by year and stratified by sexual behavior, age group, and race/ ethnicity. We also estimated the weighted percentages of persons tested for all 3 STDs (syphilis, chlamydia, and gonorrhea). We calculated percent change in each outcome from 2009-2013 and used bivariate linear regression to estimate linear trends over time in each outcome, overall and by patient characteristics. Beta coefficients for year represent the average percentage point change (divided by 100) from one year to the next. All analyses accounted for the complex sample design and weights.
RESULTS

Syphilis Testing
From 2009 to 2013, the proportion of sexually active, HIVinfected adults receiving medical care tested for syphilis increased from 55% to 65% (β = .022, P TREND < .01; Figure 1 ). The significant, increasing linear trend in syphilis testing from 2009 to 2013 was found for some but not all subgroups (Table 1) . Testing increased significantly among MSM (58% to 69%, β = .026, P TREND < .01) but not among MSW (54% to 61%, β = .016, P TREND = .20) or WSM (50% to 59%, β = .018, P TREND = .15). Significant, increasing linear trends in syphilis testing were found for all age groups with the exception of persons aged 18-29 years (60% to 66%, β = .007, P TREND = .57). By age, the largest percent change was found among persons aged 30-39 years (57% to 71%, β = .023, P TREND = .01). Testing increased significantly among white non-Hispanics (48% to 64%, β = .036, P TREND < .01) but not among black non-Hispanics (58% to 64%, β = .013, P TREND = .25), Hispanics (61% to 69%, β = .014, P TREND = .14), or persons of other race/ethnicity (55% to 60%, β = .021, P TREND = .30).
From 2009 to 2013, the proportion of sexually active, HIVinfected adults receiving medical care tested for chlamydia and gonorrhea increased from 22% to 42% (β = .040, P TREND < .01; Figure 1 ). There were significant, increasing linear trends in chlamydia and gonorrhea testing from 2009 to 2013 in every subgroup apart from persons of other race/ethnicity (Table 2) . While chlamydia and gonorrhea testing increased for WSM (27% to 45%, β = .039, P TREND < .01), the percent change was larger for MSM (22% to 43%, β = .051, P TREND < .01) and MSW (17% to 38%, β = .049, P TREND < .01). By age, the largest changes in percent tested for chlamydia and gonorrhea were among older age groups. Among those aged 40-49 years, testing increased from 21% to 43% (β = .054, P TREND < .01) and among persons aged ≥50 years, testing increased from 18% to 36% (β = .046, P TREND < .01). By race/ethnicity, the largest percent change in chlamydia and gonorrhea testing was among Hispanics (26% to 54%, β = .062, P TREND < .01), but the increase was also significant among white non-Hispanics (18% to 36%, β = .044, P TREND < .01) and black non-Hispanics (24% to 42%, β = .045, P TREND < .01). The increase in chlamydia and gonorrhea testing among persons of other race/ethnicity was not significant (29% to 36%, β = .026, P TREND = .11).
Syphilis, Chlamydia, and Gonorrhea Testing
The proportion of sexually active HIV-infected adults tested for all 3 STIs increased from 20% to 36% (β = .040, P TREND < .01; Figure 1 ).
DISCUSSION
We found significant increases in testing for syphilis, for chlamydia and gonorrhea, and for all 3 infections among sexually active HIV-infected adults receiving medical care in the United States from 2009 to 2013. However, these increases were not found among all subgroups. While testing for syphilis increased overall from 55% to 65%, the increase was significant only among MSM, persons aged ≥30 years, and white non-Hispanics. Notably, the largest percent change occurred among white non-Hispanics who had the lowest levels of syphilis testing in 2009. In contrast, we found significant increases in chlamydia and gonorrhea testing overall from 22% to 42% and in nearly every subgroup examined. In general, the largest percent change in chlamydia and gonorrhea testing from 2009 to 2013 occurred among groups with low levels of testing in 2009 (ie, MSW and persons aged >30 years). However, this was not observed by race/ethnicity. Hispanics had comparatively high levels of chlamydia and gonorrhea testing in 2009, yet still had the largest percent change. We did not identify a significant increase in chlamydia and gonorrhea testing among persons with other race/ethnicity; however, this is likely due to small sample size in this group. Despite the fact that chlamydia and gonorrhea incidence is substantially higher than the incidence of syphilis, we found that the prevalence of syphilis testing was higher than testing for chlamydia and gonorrhea overall for all subgroups and at all time points. In the United States in 2014, reported case rates were 456.1 per 100 000 persons for chlamydia, 110.7 per 100 000 persons for gonorrhea, and 6.3 per 100 000 persons for syphilis [2] . During 2000-2014, there was an increase in reported syphilis cases, which was primarily attributable to increased cases among men, specifically, MSM [2] . However, during 2013-2014, the rate increased among men and women [2] . More syphilis testing compared to other STD testing among HIV-infected persons has been noted in several studies [15, 23] and as Hoover et al reported, it is likely attributable to several factors. First, given recent increases in syphilis, especially among MSM [24, 25] , patient and provider awareness of the importance of syphilis screening may contribute to increased testing. In addition, because syphilis infection increases HIV viral load and decreases CD4 cell count in HIV-infected persons, failure to treat syphilis could result in increased risk of HIV transmission [26] [27] [28] . Finally, as a measure of quality assurance, syphilis testing is a requirement of Ryan White funding, and approximately 73% of MMP facilities received Ryan White funding in 2009-2011 [29] .
While increases in STD testing indicate improvement, testing remains far below recommended guidelines, which state that all sexually active HIV-infected persons should be screened at least annually for syphilis, chlamydia, and gonorrhea. Possible reasons why providers are not adherent to recommended guidelines include time constraints, the invasiveness of some screening tests, or personal discomfort discussing sexual behavior [30, 31] . However, effective interventions exist to increase provider's adherence to guidelines as well as patients' acceptance of screening. Examples of effective tools include electronic alerts for doctors; syphilis serology included with blood tests performed as part of HIV monitoring; educational workshops for clinic staff; Internet-based continuing medical education; free sexual health consultations for patients; biannual STD testing, coupled with brief risk-reduction counseling; and provision of a urine specimen cup at the time of patient registration [32] [33] [34] . These strategies could be used to increase routine STD screening. Our analysis has limitations. First, our estimates may underestimate STD testing in HIV-positive persons receiving care because we only collected data from the medical record at the persons' primary HIV care providers, which could miss STD testing that occurred outside of that setting. Second, MMP altered the way STD testing information was captured in 2013 such that it was easier to record tests at multiple anatomical sites on the same day; however, all trends remained significant when we limited the analysis to 2009-2012 data only (data not shown). Third, we were unable to determine if STD tests were administered as part of regular screening, as guidelines recommend, or due to the presence of symptoms. Fourth, while patients were randomly sampled each year, it is possible that a person was selected and participated in more than 1 data collection cycle. Our analysis did not account for this correlation. However, we replicated the analysis with such patients removed and results of all trend analyses remained unchanged. Last, during 2009-2013, MMP included only people who were receiving HIV medical care; therefore, our estimates are unlikely to be generalizable to all HIV-diagnosed persons in the United States.
From 2009 to 2013, testing for syphilis, chlamydia, and gonorrhea increased among sexually active HIV-infected persons receiving HIV medical care in the United States. However, in 2013, 64% of persons did not receive recommended testing for all 3 STDs. Further, syphilis testing did not increase among MSW, WSM, those aged 18-29 years, blacks, non-Hispanics, and Hispanics. Given that syphilis case rates have increased among MSM, MSW, and women in recent years and the fact that racial disparities exist, the failure to identify increased syphilis testing among all groups indicates a need for improvement. Moreover, these suboptimal testing rates are likely to be even lower among persons not receiving HIV medical care. Given the morbidity associated with STDs and their potential to increase HIV transmission, our findings suggest that enhanced efforts may be warranted to screen all HIV-infected sexually active adults for syphilis, chlamydia, and gonorrhea at all appropriate anatomical sites.
Notes
